Paul R. Kirchgraber, CEO, Covance Drug Development at LABORATORY CORP OF AMERICA HOLDINGS (LH), sold 2,500 shares at $276.55 ($691K) on 2021-05-06, disclosed to the SEC on 2021-05-10.
Open-market sale of $691k LH by CEO, Covance Drug Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| LH | SELL | 2020-11-06 | $321K | — | Filing → |